Articles tagged with Drug Studies
A study published in Human Reproduction found that men with obesity who lost weight saw a 50% increase in sperm concentration and a 40% increase in sperm count over an 8-week period. This improvement was sustained for up to 52 weeks and even doubled for those who maintained weight loss after a year
A Johns Hopkins Medicine study found that a protein called STING responds to clean-up signals in brain cells damaged by Parkinson’s disease by creating a cycle of inflammation that accelerates the disease’s progression. In mice with deactivated STING proteins, there was less microglial activity and brain cell death.
This study analyzed supportive evidence for FDA approvals of 49 novel drugs in 2020. The study's findings provide insight into the key design characteristics of pivotal trials supporting these drug approvals.
A recent study found that 70% of adults with stage 3 or 4 cancer were at risk of drug-drug interactions, highlighting the importance of deprescribing medications to avoid harm. The study's results emphasize the need for education and problem-solving to address polypharmacy in older adults with cancer.
Research on experimental drug NU-9 invents by Northwestern University scientists reveals it is more effective than existing FDA-approved drugs for ALS treatment. NU-9 also repairs the axons of diseased upper motor neurons in ALS mouse model, offering a potential new approach to treating the devastating disease.
A global study found a combination of two drugs dramatically reduces the chances of suffering an asthma attack. The combination of albuterol and budesonide lowers the number of sudden episodes of shortness of breath, wheezing, and coughing in patients.
A Rutgers study found that individuals with opioid-use disorder who used non-prescribed buprenorphine before entering treatment were twice as likely to remain in care. Those who used the medication also had significantly lower rates of opioid use during the first six months in treatment.
A new lymphoma treatment, zanubrutinib, has been found to be effective in 80% of patients with marginal zone lymphoma, resulting in significant cancer shrinkage. However, its impact on follicular lymphoma is less pronounced.
The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 12 studies as Late-Breaking Clinical Science and Featured Clinical Research. These studies highlight advances in transcatheter aortic valve replacement, mitral, tricuspid, and left atrial appendage occlusion therapies.
Researchers developed an algorithm to quickly identify two cancer drugs that work well together, reducing testing time from three years to eight weeks. The new method uses gene expression data to prioritize potential combinations and has been confirmed in lab tests.
Researchers found that targeting both tumor and lymph node microenvironments with nanomedicine improves treatment response for metastatic triple negative breast cancer. Long-term tumor remission was achieved in mice models using nanoparticles to deliver immune-modulating drugs.
A study published in JCI Insight reveals that epigenetic drugs targeting BRD4 significantly reduce scarring in patients with scleroderma. The findings could lead to repurposing these drugs for faster relief from debilitating symptoms of this chronic disease.
A new study suggests that supplementing a diet with Ascidiacea, also known as sea squirts, reverses some main signs of aging in animal models. The researchers found that plasmalogens, vital to body processes, decrease with age and contribute to neurodegenerative diseases like Alzheimer's and Parkinson's.
A Rutgers University study found that expanding prison opioid treatment programs could reduce the risk of overdose and death among ex-inmates. The researchers suggest that further education on post-release opioid risks is necessary to increase participation in these programs.
Researchers at the University of Waterloo found that combining diuretics and renin-angiotensin system inhibitors with ibuprofen can lead to acute kidney injury in people with certain medical profiles. The combination may be a 'triple whammy' that exacerbates dehydration, which is a major factor in acute kidney injury.
Scientists discovered that intermittent dosing of PI3Kδ inhibitors can reduce toxicity while maintaining anti-tumor immunity in patients with head and neck cancers. This finding holds promise for improving treatment outcomes and saving lives.
The BMJ recommends offering additional cholesterol-lowering drugs to adults at high heart disease risk, particularly those with 'bad' LDL cholesterol levels above 70 mg/dl. Ezetimibe and PCSK9 inhibitors are recommended for the high and very high risk group, but not for those in the low risk category.
Canadian and German researchers have identified personalized prescriptions that combine drugs to treat obesity and Type 2 diabetes. The combination therapy shows higher effectiveness in some patients and fewer side effects compared to single drugs. Studies are now needed to understand why individuals respond differently to the treatment.
Scientists at Scripps Research developed a new method called CATCH to image where drugs bind to their targets across different tissues and with higher precision than ever before. This technique allows for better understanding of why one drug is more potent or has a particular side effect compared to another.
Researchers at the University of Oxford have demonstrated the efficacy of adalimumab in treating early-stage Dupuytren's disease. The trial found that patients receiving adalimumab experienced softening and reduction in size of treated nodules, with sustained effects up to nine months after treatment.
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.
A new study published in the New England Journal of Medicine found that treating even mild forms of high blood pressure during pregnancy is safe and beneficial for both mother and developing baby. The study's results demonstrated a significant decrease in pregnancy complications, including severe preeclampsia and preterm births.
Researchers from Columbia University have developed a plug-and-play multi-organ chip, customized to the patient, consisting of engineered human heart, bone, liver, and skin linked by vascular flow. The model allows for long-term studies and can be optimized for personalized therapy optimization in cancer and systemic diseases.
Researchers at UMass Amherst have developed a new class of material called pZC that can withstand acidic stomach conditions and dissolve in the small intestine. This innovation could revolutionize oral medication delivery, increasing the number of medications that can be taken orally.
Researchers will enroll 1,000 adults in a placebo-controlled trial to assess the effects of low-cost phentermine on weight loss and related health metrics over two years. The study aims to provide long-term treatment options for patients struggling with obesity.
Researchers developed a disposable electrochemical sensor using graphite-based molecularly imprinted polymers to detect theophylline levels. The sensor can identify low concentrations of theophylline (2.5 μg/mL) in whole blood within 3 seconds, enabling real-time monitoring and potential overdose prevention.
A new study validates the Canadian Syncope Risk Score as a reliable tool to identify patients at low risk for serious outcomes after 30 days, potentially reducing hospitalization rates. The score showed better performance than another validated score, but its clinical utility remains uncertain and warrants further research.
Research suggests that EMFs can cause Alzheimer's disease by building up calcium levels in brain cells. This increase leads to changes in the brain, which develop conditions for Alzheimer's. The study highlights the importance of reducing EMF exposure to prevent or delay the onset of Alzheimer's.
Researchers have engineered a tiny living heart chamber replica to study disease progression and test new treatments. The miniPUMP device mimics the real organ's mechanics, allowing for accurate tracking of how the heart grows in embryos and studying the impact of disease.
A randomized controlled trial found that furosemide increases the risk of electrolyte adverse events but no difference in hearing loss or nephrocalcinosis was observed. The study suggests caution when using furosemide in preterm infants at high risk for bronchopulmonary dysplasia.
A NIH-funded study found that patients with retinal vein occlusion experience significant visual acuity gains, but require long-term monitoring and treatment. After five years, many participants retained an average of three lines of improvement in their visual acuity.
A Canadian study of over 12,000 hospital admissions found that updated product label changes did not reduce rates of accidental acetaminophen overdose. The study suggests additional measures are needed to prevent these episodes beyond just labeling changes.
A study examined the frequency of FDA's extrapolation of pivotal trial data to approved indications, finding it occurred in 45% of cases. This practice may lead to different clinical results in real-world use compared to trials.
A mutated gene in more than 20% of breast cancer recurrences promotes metastasis and resistance to hormone therapy. Researchers identify potential vulnerabilities, leading to the development of personalized treatment approaches.
A new study found that Black kidney transplant recipients exhibit a faster clearance rate of tacrolimus, an immunosuppressive drug. The study suggests that considering both sex and race when dosing tacrolimus may reduce adverse effects and enhance transplant outcomes.
A study by Cornell researchers found that recreational marijuana access significantly decreases prescriptions for pain, depression, anxiety, sleep, psychosis, and seizures in state Medicaid programs. This reduction could lead to significant cost savings for state Medicaid programs.
A phase 1–2 clinical trial led by Massachusetts General Hospital has shown promising safety and efficacy results for rilzabrutinib, an oral Bruton kinase inhibitor, in treating immune thrombocytopenia. The study found that 40% of patients experienced a significant platelet response, with minimal treatment-related adverse events.
Researchers at Tokyo University of Science discovered that disulfiram inhibits FROUNT protein and chemokine signaling pathways, reducing anxiety levels in mice. The study suggests a potential breakthrough anti-anxiety medication with safe and effective treatment for elderly patients suffering from anxiety and insomnia.
A new University of Gothenburg study has found that a drug treatment can reduce the frequency of breathing pauses in sleep apnea by an average of over 20 per hour. The treatment, which involves carbonic anhydrase inhibition, showed promising results with minimal side effects.
A new study found that valbenazine, a VMAT2 inhibitor, is safe and effective in treating chorea in patients with Huntington's disease. Chorea is a common symptom of the disease, causing involuntary and irregular movements.
Researchers at The University of Toledo found that low-dose lithium acts as a powerful anti-aging agent in the kidneys by blocking GSK3-beta, an enzyme associated with cellular aging. Studies showed improved kidney function and reduced albuminuria in mice and psychiatric patients treated with lithium.
Researchers at Rutgers University propose a new approach to COVID-19 vaccine testing by combining conventional and challenge trials. This parallel approach, called Combining Conventional and Challenge trials (CCC), aims to facilitate faster and more accurate vaccine assessment and more effective pandemic response.
Researchers developed a bioinformatics platform called REFLECT to predict optimal combination therapies based on co-occurring tumor alterations. The tool selected combinations that resulted in improved patient outcomes across pre-clinical and clinical studies, leading to increased durable responses.
A systematic review and meta-analysis found that SGLT2 inhibitors reduce hospitalizations and cardiovascular deaths in heart failure patients, regardless of diabetes status. The analysis also warned of increased genital infections associated with treatment.
Researchers found that combining durvalumab with novel agents like oleclumab and monalizumab increased major pathological response rates compared to solo durvalumab. The study also identified key immune cell signatures associated with treatment outcomes.
A phase two randomised placebo controlled trial showed giving patients nintedanib, as well as chemotherapy before surgery or radiotherapy, significantly increased overall survival rates at one, two and five years. Nintedanib blocks different proteins from sending signals to cancer cells to grow, causing the cancer cells to die.
A new analysis of brain scans from close to 60 people receiving treatment for depression reveals that psilocybin-assisted therapy shows increased brain connectivity even after use, leading to self-reported improvements in depression. The findings differ from conventional antidepressants and suggest a fundamental mechanism via which psy...
The RACE Act has led to an increase in required studies for cancer drugs targeting molecular targets relevant to pediatric cancer. Since its implementation, 42.9% of approved drugs have been required to conduct pediatric studies, up from 8.3% before the act.
Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.
Researchers developed innovative smart sensors to test new vaccines, revealing significant discrepancies between subjective self-reports and objective measurements. The study found that side effects escalate over the first 48 hours and then stabilize, with parameters returning to pre-vaccination levels.
A new study found that less than half of clinical trials reported race/ethnicity data, with minorities underrepresented despite efforts to increase diversity. Industry-funded studies had the greatest gaps in enrolling minority participants.
Researchers developed an AI model to predict side effects from new combination therapies by analyzing over 15 million records of adverse events. The model can recognize patterns between drugs and their side effects, enabling the prediction of adverse events for individual therapy profiles.
A large US study confirms a strong link between ED medications and vision problems, including an 85% increased risk of developing serious eye conditions. Regular use of Viagra, Cialis, Levitra, or Stendra may lead to side effects such as age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Recent studies published in the Journal of Pharmaceutical Analysis have found applications of nanotechnology in medicine, drug research, and environmental protection. Researchers developed nanodots made of carbon using natural polysaccharides from mushrooms to detect chromium, and created nanozymes that could be used to detect drug con...
Research reveals nearly a third of pregnant Medicaid beneficiaries screened for hepatitis C test positive, but fewer than a fifth receive follow-up care. A sustainable pathway to treatment is crucial, especially with expanded postpartum Medicaid coverage and highly effective oral medications.
A randomized clinical trial found that participants treated at non-stigmatizing 'accessible care' centers were nearly three times more likely to be cured of hepatitis C than those referred out to local clinicians. The study suggests that expanding and supporting accessible care models could help eliminate the disease.
Researchers at University of Oxford and Leeds found liposomal bupivacaine no more effective than current treatments for post-operative knee pain. The SPAARK Trial showed that the drug did not improve recovery or pain relief compared to bupivacaine hydrochloride alone.
A clinical trial reveals that lamivudine, a widely used HIV treatment, halted disease progression in 28% of patients with fourth-line metastatic colorectal cancer. The study suggests an unexpected promising direction for cancer treatment and encourages the exploration of pairing reverse transcriptase inhibitor therapy with immunotherapy.
A study of patients treated with edoxaban and dual antiplatelet therapy (DAPT) after TAVR found that edoxaban reduced subclinical leaflet thrombosis, but did not affect stroke risk. Rates of death, stroke, and cognitive decline were similar in both groups.
The study found that TAVR resulted in significantly less structural valve deterioration after five years compared to SAVR. Patients with structural valve deterioration were at about twice the risk of death or rehospitalization as those without, highlighting the benefits of TAVR in reducing mortality and hospitalization risks.